Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL Phase 3 Study of ION582 in Angelman Syndrome
jRCT2051250098Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of obudanersen in Angelman syndrome (AS) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Expressive communication (Bayley-4) change. Started Aug 2025; status: recruiting.
02
Drugs
obudanersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on jRCT2051250098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250098.